Atlas Trials

Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML

Clinical trial NCT02091245 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT02091245
Sponsor
Dana-Farber Cancer Institute
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Relapsed Acute Lymphoblastic Leukemia (ALL)Refractory Acute Lymphoblastic Leukemia (ALL)Relapsed Acute Myelogenous Leukemia (AML)Refractory Acute Myelogenous Leukemia (AML)Relapsed Mixed Lineage LeukemiaRefractory Mixed Lineage LeukemiaRelapsed Biphenotypic LeukemiaRefractory Biphenotypic LeukemiaChronic Myelogenous Leukemia (CML) in Blast Crisis
Start date
2014-03-01
Primary completion
2018-02-01
Enrollment
16

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.